Cultured human endothelial cells synthesize prostacyclin (PGI) a potent inhibitor of platelet function, when stimulated with histamine, bradykinin, or ATP. Paradoxically, we report that these agonists also induced the rapid and sustained synthesis of platelet-activating factor (PAF) by endothelial cells. In fact, the synthesis of this potent activator of platelets and neutrophils was induced by stimulation of the same receptor subtype that induced PG12 synthesis: stimulation of a histamine HI or a bradykinin B2 receptor induced both PAF and PGI2 synthesis. However, two physiologically important differences exist between the production of PAF and PGI2 by endothelial cells. The synthesis of PGI2 proceeded for only 7.5 min before the abrupt termination of synthesis, whereas the synthesis of PAF was clearly detectable even 45 min after stimulation. Although
Introduction
Vascular endothelium is composed of a single layer of endothelial cells that mediates the interaction of the blood with the rest of the organism. Among the functions demonstrated by endothelial cells is the presentation of a surface that does not activate the hemostatic system and thereby induce the formation of thrombi. This property is not shared by either the substratum or the smooth muscle cells and fibroblasts that underlie the endothelium. The difference in the endothelial cell surface that results in thromboresistance is not defined, but it is known that endothelium (1) and cultured endothelial cells (2) synthesize prostacyclin (PGO2)' in response to a number of physiologic stimuli (3) (4) (5) (6) (7) . Initially, the synthesis of this potent inhibitor of platelet aggregation and activation was postulated to participate in the maintenance of a nonthrombogenic surface (1) . However, it is now apparent that endothelial cells secrete little, if any, PGI2 in the absence of appropriate agonists, and inhibition of the cyclooxygenase activity with aspirin does not alter the adhesion of platelets to unstimulated endothelium (8) . The role of PGI2 is further obscured by the observation that stimulation of the endothelium with thrombin, a potent agonist for PGI2 secretion, actually results in the loss of thromboresistance (8, 9) .
The recent observation (10, I 1) that endothelial cells make platelet-activating factor (PAF) in response to physiologic concentrations of thrombin may explain the generation of a thrombogenic surface in response to this agent. PAF, identified as l-alkyl-2-acetyl-sn-glycero-3-phosphocholine (12) , has the unusual property of being a potent agonist for the activation of both platelets and granulocytes (13) , and treatment of endothelial cells with thrombin has been shown to increase the adhesion of granulocytes (10) and platelets (8) to the cell monolayer.
The synthesis of both PAF and PGI2 in response to thrombin was unanticipated due to the potent, but opposing actions of these two agents on platelet and neutrophil function. Inasmuch as the nature of the endothelial cell recognition system for thrombin has not yet been explicitly defined, it is possible that thrombin induces two separate signals, and that the co-stimulation of PAF and PG12 synthesis is coincidental. In order to understand better the relationship between the synthesis of PAF and PGI2, agonists that prompt endothelial cells to synthesize PGI2 by a receptor-mediated mechanism were examined for their potential to also induce the synthesis of PAF. We found that agonists that promoted endothelial cell synthesis of PG12, namely, histamine (4), bradykinin (5) , and ATP (7), induced the synthesis of PAF Human endothelial cells were harvested from umbilical veins and grown to confluence in gelatin-coated 35-mm tissue culture dishes as previously described (10) . Agonist-stimulated PAF accumulation was determined by using a slight modification of our previous protocol (10) . The assay was initiated by replacing the growth medium with I ml of Hanks' buffered saline-10 mM N-2-hydroxyethyl-piperazine-N'-2-ethanesulfonic acid (Hepes), pH 7.4, containing 25 ,uCi of carrierfree [3H]acetate. After incubation at room temperature for the stated time, the assay was terminated by the addition of 0.5 ml of 50 mM acetic acid in methanol. Labeling at this temperature resulted in only marginally less radioactivity incorporated into PAF than when the cells were labeled at 370 (13a). The cells remained viable and responsive in this serum-free buffer for 15 h, a period of time much longer than any incubation used in this study.
The material from all terminated assays was collected as follows: cells in acidified medium were scraped from the plate; the plate was washed twice with I ml of methanol; 7 nmol carrier PAF were added; and 1.25 ml of chloroform was added to the pooled fluid to form a monophase (14) . The monophase was split with CHC13 and 0.1 M NaAc, and the lower phase was washed three times with preequilibrated upper phase. This was dried under N2 and the lipids were resuspended in CHCl3/MeOH (9:1) . An aliquot of the recovered lipids was used to determine the total amount of radioactivity present, while the remainder was fractionated by thin-layer chromatography (TLC) that used silica gel 60 (Merck & Co., Darmstadt, Federal Republic of Germany) and solvent system II of Mueller et al. (15) . Areas containing PAF, identified by H20 misting, and the remainder of the lane were separately scraped into scintillation vials for quantitation. Duplicate assays show that the mean variation of PAF production by cultures derived from the same vein was ±5%. Chromatography in a second TLC system (16) showed that [3H]acetate-labeled lipids elicited by histamine, bradykinin, or ATP migrated with authentic 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine. Treatment of each of these radiolabeled lipids with Crotalus adamanteus phospholipase A2 (10) showed that at least 90% of the radioactivity was incorporated into the sn-2 5) while the resting tension was stabilized at 2 g. Agents were tested by stopping this flow, adding the agent to the 10-ml organ bath that was continuously bubbled with the 02/CO2 mixture, and recording the strain gauge output with a strip-chart recorder. The effector compounds were removed by reinitiating buffer flow.
Results
Human endothelial cells make PAF in response to histamine. The addition of histamine to the cultured cells resulted in the immediate induction of cellular PAF synthesis (Fig. 2 B) . Accumulation of PAF by endothelial cells increased with time during the first 10 min of histamine stimulation. Half of this accumulated PAF was then lost in the succeeding 5 min of incubation, followed by a slower rate of loss over the next 45 min. This pattern resulted in measurable amounts of cellassociated PAF for up to I h after the initiation of histamine stimulation.
The duration of the accumulation of PAF by endothelial cells in response to histamine was markedly different from the time course of histamine-elicited PGI2 release from endothelial cells. The quantitation of 6-keto-PGFI,, the stable degradation product of PGI2, by radioimmunoassay showed that unstimulated monolayers released little PGI2 to the medium (Fig. 3) . Histamine stimulation induced the linear accumulation of 6- keto-PGF1, in the medium for 7.5 min before the abrupt termination of this accumulation. This pattern of 6-keto-PGF1, accumulation was identical (Fig. 3) to that produced by thrombin, another agonist for PAF synthesis (10) . The cessation of 6-keto-PGFIa accumulation at 7.5 min shows that PGI2 synthesis was terminated or sharply reduced by this time. Thus, whereas endothelial cells synthesize both PAF and PGI2 in response to histamine and thrombin (10) , the presence of endothelial cell PAF persisted well beyond the burst of PGI2 synthesis and release from the cell monolayer.
Histamine stimulates both PAF and PGI2 synthesis via an HI receptor. Stimulation of PGI2 synthesis by human endothelial cells in response to histamine has been shown to be mediated through an HI-type receptor (4) . The data in After 5 min at 240C, the incubation was stopped with acidic methanol as described in Methods. The material to be tested for bioactivity was derived from two pooled culture plates and carrier PAF was not added to this extraction. Extracted lipids were injected onto a 4.6 X 300-mm Micropak Si-S HPLC column and eluted at 1 ml/min as described (17) . Fractions were collected at 0.5-min intervals and the radioactivity in the entire fraction was quantitated.
Fractions from unlabeled cells were prepared for bioassay as described (21) . The resulting data (Fig. 4) (Table  III) . This stimulation of PAF synthesis was time-dependent ( ATP by cultured endothelial cells (22) . However, the presence of the hydrolysis products ADP, AMP, or adenosine was not responsible for ATP bioactivity as these compounds were unable to induce PAF synthesis (Table III (Table III) . This is consistent with the previous demonstration (7) time-dependent (not shown) and amounted to about twice the amount induced by exchanging growth medium for assay buffer ("control"). Other phosphorylated adenosine derivatives, the 3,'y-methylene-ATP analogue, or adenosine itself did not induce PGI2 synthesis. Thus, ATP induced the synthesis of both PAF and PGI2 by stimulation of what appeared to be a common, or very similar, mechanism.
PAF remains cell-associated. We have previously observed that the PAF elicited upon thrombin stimulation of endothelial cells was not released into the medium, but instead remained associated with the cell monolayer (10) . Fig. 7 shows that the PAF synthesized in response to histamine, Met-Lys-bradykinin or ATP was also localized to the endothelial cells. Separation of the assay medium from the cell monolayer showed that 99% of the radiolabeled PAF synthesized in response to any agonist was associated with the cells, and that release of PAF was increased to no more than 2% of the total [3H]PAF even when physiologic concentrations of albumin were included in the assay buffer. For comparison, the relative amount of PAF excreted from thrombin-stimulated cells in this experiment in the presence of 50 mg/ml bovine serum albumin (BSA) was 0.6%. Such data show that endothelial cell-generated PAF is not likely to be secreted from the endothelium and this PAF cannot function as a hormone.
PAF is not an endothelium-derived relaxing factor. The agonists thrombin, histamine, bradykinin, and ATP have been shown to induce endothelium to elaborate an unidentified vasodilator (18, 23), termed endothelial-derived relaxing factor, or EDRF, that mediates the vasodilation induced by these agonists. In that PAF is a potent hypotensive agent (24) is an EDRF. The assay for EDRF activity employed an ex vivo arterial ring preparation, derived from a canine femoral artery, equilibrated at a stable resting tension of 2 g. Addition of norepinephrine to the ring (Fig. 8 ) resulted in a strong contraction, indicating that the arterial smooth muscle was viable. The addition of acetylcholine to the contracted ring caused a relaxation to 60% of the maximal tension. Reinitiation of the flow of perfusate removed these effectors and allowed the ring to return to its resting tension. The addition of PAF to this relaxed ring did not induce a contractile response, nor did it interfere with the subsequent norepinephrine-induced contraction. The ability of the ring to contract had not been altered by the previous manipulations inasmuch as the tension generated during the second contraction was identical to that of the initial response. The addition of PAF to the contracted arterial ring did not induce the relaxation of this tissue. The small increase in tension upon the addition of PAF also occurred when the washout of the preparation was initiated.
From these results, we conclude that PAF does not directly affect arterial vascular tone and is not an EDRF.
Discussion BSA CONCENTRATION (mg/ml) Figure 7 . PAF remains associated with endothelial cells. The localization of histamine-, bradykinin-, or ATP-elicited PAF was examined in the absence or in the presence of increasing concentrations of essentially fatty acid-free BSA in the assay medium. After a 10-min stimulation, the medium was removed, the cell monolayer and its supernatant were acidified with HOAc in methanol, and these fractions were separately processed as described in Methods. The data is presented as the percentage of total counts associated with the fraction. The total amount of [3H]PAF generated in BSA-free assay medium was: thrombin, 11,430 cpm; histamine (x), 3,515 cpm; MetLys-bradykinin (-), 407 cpm; ATP (o), 1,844 cpm. The association of PAF with the cell monolayer, rather than release of the newly synthesized PAF into the bathing medium, has been observed in six separate experiments.
Human endothelial cells in culture are stimulated by thrombin, histamine, bradykinin, and extracellular ATP. These compounds are vasoactive agonists that mediate reactions in the coagulation pathway and in the acute inflammatory response. The endothelial cell response to these agonists previously has been characterized as the induction of PGI2 synthesis (3-7 Table IV show that, although histamine, bradykinin, and ATP were less potent than thrombin, these agonists still cause a substantial, and presumably physiologically significant, accumulation of PAF. The amount of PAF and PGI2 synthesized by endothelial cells was variable, which was a reflection of the variation among primary cultures derived from different umbilical veins. Duplicate assays using cells from the same source were within 5% of the mean value. Such variability of primary cultures of human endothelial cells has also been observed for histamine stimulation of prostacyclin production (Baenziger, N. L., personal communication).
Accumulation of PAF as a result of agonist stimulation of endothelial cell receptors was an immediate response. This accumulation proceeded linearly during the initial 5 min of stimulation and reached its maximal value in 10-15 min. Although the subsequent decline proceeded at a variable rate, the rate was sufficiently slow so that the amount of PAF (26, 27) .
Endothelial cells synthesized both PAF and PGI2 in response to exogenous ATP. The specificity demonstrated by endothelial cells for exogenous ATP, or deoxy-ATP, to induce the synthesis of PAF and PGI2 suggests that a single type of receptor may mediate the activation of both synthetic pathways. The human endothelial cell ATP receptor does not display the accepted specificity of a P1-purinergic receptor (28) , nor does the human umbilical endothelial cell display the P2-purinergic receptor responsible for the ATP-, ADP-, or #,-y-imido-ATP-dependent release of PGI2 from cultured porcine or bovine aortic endothelial cells (7, 29) . The synthesis of both PAF and PGI2 by human endothelial cells most closely resembles the ATP-or deoxy-ATP-specific release of histamine from rat mast cells (30). Stimulation of ATP receptors by ATP may occur in response to two sources of extracellular ATP: secretion of the contents of platelet-dense granules releases nearly as much ATP as ADP; and thrombin stimulation of human endothelial cells causes the selective release of a majority of the ATP pool of the cell (22) . The presence of extracellular ATP in vivo is also suggested by an endothelial cell ecto-ATP hydrolase activity (22) . The rapid hydrolysis of extracellular ATP by this activity may serve to limit the stimulation of PAF and PGI2 by secreted ATP.
We have employed agonists and antagonists specific for histamine or bradykinin receptor subtypes to show that the induction of both PAF and PGI2 synthesis proceeds from the stimulation of a single receptor subtype. Specifically, this was a histamine H1 or a bradykinin B2 receptor. The inflammatory response induced by agents such as bradykinin and histamine may depend upon this concerted synthesis of PAF and PGI2.
The actions of histamine previously have been characterized as the direct inhibition of polymorphonuclear neutrophil (PMN) function (31) , as well as the synthesis by endothelium of the polymorphonuclear leukocyte inhibitor, PGI2 (4) . PAF is the first activator of inflammatory cell types found to be synthesized in response to histamine and bradykinin. Thus, this endothelial cell-associated PAF may recruit inflammatory cell types to the site of inflammation and then activate them. PGI2, which temporarily may antagonize the effect of PAF on blood-borne cells, may aid this PAF-mediated cellular recruitment through capillary bed vasodilation and increased blood flow. There is as yet no evidence that-PAF can directly participate in this vasodilation. Although PAF will cause profound hypotension upon injection into a test animal (24, 32) , and the same agonists that induce endothelial cell PAF synthesis also induce the synthesis of EDRF (23), PAF was shown to have no effect on the vascular smooth muscle tension of a major vessel. The (33) .
Endothelium normally presents a nonthrombotic surface to the lumen of the vessel, yet under some circumstances it does become thrombogenic. The demonstration that human endothelial cells synthesize and retain PAF in response to physiologic agonists may be a mechanism by which this alteration is effected. The association of PAF with endothelial cells was not altered by the presence of physiologic concentrations of albumin, which is capable of sequestering PAF (34) . Although this PAF was not readily extractable, phospholipase digestion indicates that at least a portion of this PAF is present at the cell surface (Prescott, S. M., G. A. Zimmerman, and T. M. McIntyre, unpublished observations). Alteration of the surface of the endothelium and the enhanced binding and activation of neutrophils and platelets would have several sequelae: thrombus formation; damage of the endothelium by degradative enzymes and activated oxygen species; access of blood-borne elements, including lipoproteins, to the subendothelial space; and the release of platelet-derived growth factor, a potent smooth muscle and fibroblast mitogen. Several of these potential consequences have been hypothesized to be pathogenic events in the formation of an atherosclerotic plaque (35) and in other forms of vascular injury (36) . The coinduction of PGI2 synthesis might temporarily counteract these events, due to its short-lived synthesis, but also may potentiate these cell-mediated sequelae through vasodilation-induced cell recruitment. The production of PAF by endothelium may also function as a homeostatic process. Platelets have been shown to possess an endothelial cell growth factor (37), and it is known that in some manner platelets are required for the maintenance of vascular integrity (38, 39) . In addition, PAF has recently been shown to induce angiogenesis in the chick chorio-allantoic membrane (40). It is apparent that through the induction of PAF synthesis and accumulation by endothelial cells, and the co-induction of PGI2 synthesis, that the endothelium can be an active participant in inflammatory, homeostatic, and pathologic processes.
